ERR2598273
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 24
- umap1_2d
- -4.742043118
- umap2_2d
- -3.641094559
- umap1_3d
- 3.640176115
- umap2_3d
- 1.522059189
- umap3_3d
- -0.786852156
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.240
- MYOGENESIS+0.160
- PROTEIN_SECRETION+0.150
- INTERFERON_GAMMA_RESPONSE+0.120
- SPERMATOGENESIS+0.110
- UV_RESPONSE_UP+0.110
- ANDROGEN_RESPONSE+0.100
- BILE_ACID_METABOLISM+0.090
- INTERFERON_ALPHA_RESPONSE+0.090
- ADIPOGENESIS+0.080
Top 10 suppressed
- E2F_TARGETS-0.510
- MYC_TARGETS_V1-0.510
- G2M_CHECKPOINT-0.480
- MYC_TARGETS_V2-0.440
- TGF_BETA_SIGNALING-0.420
- WNT_BETA_CATENIN_SIGNALING-0.420
- NOTCH_SIGNALING-0.380
- ANGIOGENESIS-0.360
- CHOLESTEROL_HOMEOSTASIS-0.360
- DNA_REPAIR-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598272 | fetal | fetal | 0.902 |
| 2 | ERR2598331 | fetal | fetal | 0.880 |
| 3 | ERR2598274 | fetal | fetal | 0.879 |
| 4 | ERR2598330 | fetal | fetal | 0.849 |
| 5 | ERR2598271 | fetal | fetal | 0.847 |
| 6 | ERR2598293 | fetal | fetal | 0.840 |
| 7 | MDT-AP-0854 | Med | Medulloblastoma | 0.830 |
| 8 | ERR2278856 | — | — | 0.798 |
| 9 | TCGA-O1-A52J-01A-11R-A262-07 | — | cohortA1 | 0.797 |
| 10 | MDT-AP-0810 | Med | Medulloblastoma | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.120 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.020 | Inavolisib | — uncovered |